Led by President and CEO Tom Polen, BD last year secured a $24 million investment from the federal government to scale up U.S. manufacturing production of its COVID-19 rapid diagnosis testing kits.
And BD’s new Veritor Plus System can reliably test for COVID-19 and flu types A and B, making it a potentially game-changing technology. The company received an emergency use authorization for Veritor from the Food and Drug Administration in March.
As are many manufacturers, BD is evolving. In December, the company chose a name and leadership team for its spinoff Diabetes Care business. The new publicly traded entity will be called embecta. “The Diabetes Care business can trace its roots back nearly 100 years to BD’s introduction of the world’s first specialized insulin syringe in 1924 and today is the leading producer of diabetes injection devices in the world,” Polen said. “We’re proud to see that shared legacy reflected in the new name.”[/vc_column_text][/vc_column][/vc_row]
1 of 1 article
0 articles remaining
Advance your business edge with news from NJBiz. Register now for more article access.
